GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Pulmatrix Inc.
Pulmatrix is a biotech company developing inhaled medications. Its stock price is a bet on its technology for delivering medications directly to the lungs. Its price is volatile and driven by news of clinical trials and partnerships.
Share prices of companies in the market segment - Pharma other
Pulmatrix is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases using its proprietary dry powder technology. We've classified it in "Other Pharmaceuticals." The chart below shows how investors evaluate new drug delivery methods.
Broad Market Index - GURU.Markets
Pulmatrix is a biotech company developing inhaled medications for the treatment of respiratory diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Pulmatrix shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
PULM - Daily change in the company's share price Pulmatrix Inc.
For Pulmatrix, Inc., a company developing inhaled medications, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in this innovative pharmaceutical niche.
Daily change in the price of a set of shares in a market segment - Pharma other
Pulmatrix, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with PULM, which focuses on inhalation drugs, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Pulmatrix is a pharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its shares, like many in the sector, are volatile and react to news about clinical trials. These movements are part of the overall stock market landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Pulmatrix Inc.
Pulmatrix, Inc.'s year-over-year performance is a story about the development of its inhalation drug delivery platform. Its 12-month market cap depends entirely on progress in clinical trials of its respiratory disease treatments. Success in its iSPERSE™ technology could offer a more effective way to deliver drugs directly to the lungs.
Annual dynamics of market capitalization of the market segment - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Pulmatrix, a biotech company developing inhaled medications, is a company whose value is locked into its scientific platform. Its stock performance relative to the market reflects investor expectations for clinical trial success. Positive news can trigger a sharp rally, completely ignoring the broader market backdrop.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Pulmatrix Inc.
Pulmatrix is a biopharmaceutical company developing inhaled medications. Its monthly performance is entirely dependent on the results of its clinical trials. News about the progress of its respiratory treatment programs is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma other
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. Their technology delivers medications directly to the lungs, increasing their effectiveness. The graph below illustrates the overall dynamics in the pharmaceutical sector, where innovative drug delivery methods can lead to breakthroughs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Early-stage biotech stocks are a venture bet on science. The chart below shows investors' overall risk appetite. Is Pulmatrix, Inc. moving at an extreme amplitude, amplifying market movements, as is typical in such stories?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Pulmatrix Inc.
Pulmatrix, which develops inhaled medications for the treatment of lung diseases, is extremely sensitive to news. Its weekly stock price is a direct reaction to clinical trial data for its drugs, which may offer new ways to deliver medications directly to the lungs, and to FDA decisions.
Weekly dynamics of market capitalization of the market segment - Pharma other
Pulmatrix operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire segment. The chart will reveal whether PULM is moving with the industry or whether its unique inhalation technology is forging its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Pulmatrix, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how PULM shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
PULM - Market capitalization of the company Pulmatrix Inc.
The Pulmatrix chart tells the story of inhalation drug development. The company creates powdered forms of drugs for the treatment of lung diseases. Its market capitalization reflects how investors view its technological platform and progress in clinical trials, where any outcome can dramatically change its value.
PULM - Share of the company's market capitalization Pulmatrix Inc. within the market segment - Pharma other
Pulmatrix develops inhaled medications for the treatment of respiratory diseases using its iSPERSE technology. Its market share is based on the potential of this delivery platform. The chart shows how the market perceives its ability to create more effective and convenient treatments for lung diseases.
Market capitalization of the market segment - Pharma other
Pulmatrix develops inhaled medications for the treatment of lung diseases. The chart below shows the pharmaceutical sector's market capitalization. This represents a market where an innovative method of delivering medication directly to the lungs could significantly improve its effectiveness.
Market capitalization of all companies included in a broad market index - GURU.Markets
Pulmatrix develops inhaled medications for the treatment of respiratory diseases using its iSPERSE platform. Its market capitalization is a bet on this technology. The chart below shows the economic weight of companies with innovative drug delivery platforms.
Book value capitalization of the company, segment and market as a whole
PULM - Book value capitalization of the company Pulmatrix Inc.
Pulmatrix is based on inhalation technology. The company's book value reflects its patents for the iSPERSE™ platform, which delivers dry powder medications deep into the lungs, and the cash flow for its clinical use. The chart below shows the financial basis for this innovative drug delivery technology.
PULM - Share of the company's book capitalization Pulmatrix Inc. within the market segment - Pharma other
Pulmatrix, Inc., a biopharmaceutical company, is focused on R&D. Its laboratories are its primary physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a company in the research stage.
Market segment balance sheet capitalization - Pharma other
Pulmatrix develops inhaled medications. Its value lies in its unique iSPERSE™ lung drug delivery technology. A chart of its book value shows that its assets are almost entirely intangible, reflecting a focus on research rather than manufacturing.
Book value of all companies included in the broad market index - GURU.Markets
Pulmatrix's assets include inhalation drug delivery technology. The company's book value reflects its R&D laboratories and the rights to the iSPERSE™ platform, which enables dry powder delivery deep into the lungs. This provides the foundation for the development of more effective inhalation medications for the treatment of respiratory diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Pulmatrix Inc.
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. Its book value is small. Its market capitalization is based on its proprietary iSPERSE drug delivery technology and the clinical trial potential of its drug candidates.
Market to book capitalization ratio in a market segment - Pharma other
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. Its value lies in its drug delivery technology. The chart shows how the market values its platform's potential for developing new treatments compared to its tangible assets.
Market to book capitalization ratio for the market as a whole
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. The company's value lies in its patented technology for delivering medications directly to the lungs. The chart shows the market's perception of this technology platform, which can be applied to a variety of conditions.
Debts of the company, segment and market as a whole
PULM - Company debts Pulmatrix Inc.
Pulmatrix, a biopharmaceutical company developing inhaled drugs, is using debt to finance its clinical trials. This chart shows how the company is raising capital to develop and test its dry powder formulations for the treatment of respiratory diseases.
Market segment debts - Pharma other
Pulmatrix is a clinical-stage biotech company developing inhaled medications for the treatment of respiratory diseases. Its future depends entirely on the results of clinical trials and its ability to attract funding. This chart shows its cash reserves and the rate at which they are spent on R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Pulmatrix Inc.
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. This chart shows whether the company is raising debt for its development. For a company in the clinical trial stage, with no revenue, any level of debt creates significant pressure and risk for shareholders.
Market segment debt to market segment book capitalization - Pharma other
Pulmatrix, Inc. develops inhalation medications. For the pharmaceutical industry, this chart reflects general trends in R&D funding and the commercialization of new drugs. It provides context for assessing the company's financial strategy, particularly in its niche of inhalation therapy, which requires specialized equipment.
Debt to book value of all companies in the market
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. Their iSPERSE technology delivers medications directly to the lungs. This chart, showing the market's debt-to-book value ratio, is important for assessing the biotech investment climate, which affects Pulmatrix's ability to fund its clinical research.
P/E of the company, segment and market as a whole
P/E - Pulmatrix Inc.
Pulmatrix develops inhaled medications for respiratory diseases using its iSPERSE technology. This chart reflects the company's confidence in its drug delivery platform. Its value shows how willing investors are to invest in a technology that promises more effective drug delivery directly to the lungs, potentially improving treatment.
P/E of the market segment - Pharma other
Pulmatrix, Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. Comparing the company's P/E to this benchmark provides insight into how highly the market values its iSPERSE inhalation platform compared to the average prospects of other biotech companies.
P/E of the market as a whole
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. Its iSPERSE technology delivers medications directly to the lungs as a dry powder. This chart shows the current sentiment in the pharmaceutical sector. The company's valuation depends on the success of its platform in clinical trials and its ability to secure partnerships with major pharmaceutical companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Pulmatrix Inc.
Pulmatrix is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. The chart reflects future revenue expectations, which depend on the success of clinical trials and the commercialization of its iSPERSE technology platform for drug delivery to the lungs.
%20P%2FE%20Pulmatrix%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Pulmatrix-Inc.&v=1772513525434 "Chart of the company's future (projected) P/E Pulmatrix Inc.")
Future (projected) P/E of the market segment - Pharma other
Pulmatrix develops inhaled medications for the treatment of severe lung diseases using its proprietary dry powder technology. This chart shows how its future revenue expectations compare to the industry average, reflecting its innovative approach to delivering medications directly to the lungs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772513525510 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Pulmatrix is a biotech company developing inhaled medications for the treatment of respiratory diseases. Its valuation is based on the potential of its iSPERSE technology platform. Success depends on clinical trial data, not on the overall market forecasts shown in this chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513525537 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Pulmatrix Inc.
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. It uses its proprietary technology to deliver drugs directly to the lungs. Being in the R&D stage, it incurs significant expenses. This chart reflects its investments in the development of new treatments for lung diseases.
Profit of companies in the market segment - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. This chart shows the profitability of its segment. Its unique dry inhalation platform has the potential to improve drug delivery to the lungs. R&D costs impact current overall profitability, but success could create a new standard of care.
Overall market profit
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its future depends on the success of clinical trials and regulatory approval. This chart illustrates general economic cycles as Pulmatrix develops innovative treatments that address specific medical needs.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Pulmatrix Inc.
Pulmatrix, Inc. develops inhaled medications for the treatment of respiratory diseases using its proprietary iSPERSE technology. This chart reflects analysts' expectations for future revenue, which depend on the success of clinical trials and partnerships with major pharmaceutical companies to commercialize its products.
%20profit%20of%20the%20company%20Pulmatrix%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Pulmatrix-Inc.&v=1772513525731 "Graph of future (projected) profit of the company Pulmatrix Inc.")
Future (predicted) profit of companies in the market segment - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. This chart shows profitability projections for the pharmaceutical sector. It reflects expectations for innovative methods of delivering drugs directly to the lungs.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772513525797 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Pulmatrix develops inhalation medications. For a biotech company in the research stage, market profit forecasts are important as an indicator of funding availability. During periods of economic optimism, investors are more willing to invest in risky biotech companies, which is vital for advancing their developments through clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513525837 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Pulmatrix Inc.
Pulmatrix, Inc. develops inhaled medications for the treatment of respiratory diseases. Being in the clinical stage, the company has no stable revenue. P/S will be important after the product launch to assess the commercial potential of its innovative drug delivery technology.
P/S market segment - Pharma other
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases using its proprietary iSPERSE dry powder technology. This chart shows how the market is evaluating their innovative delivery platform and pipeline of candidates for the treatment of pulmonary diseases.
P/S of the market as a whole
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. The company has no commercial revenue, and its valuation depends on the success of clinical trials. This chart, showing its estimated real revenue, highlights Pulmatrix's high-risk bet on innovation in lung disease treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Pulmatrix Inc.
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its technology delivers medications directly to the lungs. This chart reflects investor expectations for future revenue from its inhaled therapies if they successfully complete clinical trials.
%20P%2FS%20Pulmatrix%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Pulmatrix-Inc.&v=1772513525901 "The graph of the company's future (projected) P/S Pulmatrix Inc.")
Future (projected) P/S of the market segment - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases using its proprietary iSPERSE™ technology. This chart shows how the market perceives the future potential of its drug delivery platform. It compares it to other pharmaceutical companies, reflecting its niche in pulmonology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772513525912 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Pulmatrix develops inhaled medications for the treatment of respiratory diseases. The company's technology delivers medications directly to the lungs, enhancing their effectiveness. This chart shows overall revenue projections, and PULM demonstrates how innovations in drug delivery systems can improve treatment and create new therapeutic opportunities.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513525933 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Pulmatrix Inc.
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Because its products are in development, the company has no sales revenue. Any revenue reflected in this chart likely comes from licensing or partnership agreements.
Sales of companies in the market segment - Pharma other
Pulmatrix is a biopharmaceutical company developing inhaled drugs. At this stage, its revenue is likely derived from partnerships. This chart allows investors to assess financial support from major pharmaceutical companies, which is key to continued development.
Overall market sales
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. The need for these treatments is not dependent on the economic situation. This schedule is not a factor for Pulmatrix, whose success depends on the results of clinical trials and regulatory approval.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Pulmatrix Inc.
Pulmatrix is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its revenue forecast depends on the success of clinical trials and partnerships. This chart shows analysts' speculative expectations for its iSPERSE technology platform.
%20sales%20of%20the%20company%20Pulmatrix%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Pulmatrix-Inc.&v=1772513525968 "Schedule of future (projected) sales of the company Pulmatrix Inc.")
Future (projected) sales of companies in the market segment - Pharma other
Pulmatrix, Inc. develops inhaled medications for the treatment of respiratory diseases. This chart shows projected revenue for the entire pharmaceutical sector. For a company focused on innovative delivery technology, general industry trends help assess the potential of their iSPERSE platform across various therapeutic areas.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772513525975 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Pulmatrix is a biotech company developing inhaled medications for the treatment of respiratory diseases. Its success depends on the results of clinical trials and partnerships. This graph of overall market expectations reflects the investment climate. A positive environment facilitates raising the capital needed to finance long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513525994 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Pulmatrix Inc.
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. This chart reflects the company's current status in clinical development. It demonstrates the company's investment in research, the success of which determines its future.
Market segment marginality - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled therapies for the treatment of severe lung diseases using its iSPERSE platform. This chart reflects the average profitability in the pharmaceutical sector. It helps assess the commercial potential of Pulmatrix's innovative drug delivery technology in this market.
Market marginality as a whole
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its future depends on the success of clinical trials. This overall market profitability graph is irrelevant to Pulmatrix's valuation, which is a bet on the effectiveness of its drug delivery technology.
Employees in the company, segment and market as a whole
Number of employees in the company Pulmatrix Inc.
Pulmatrix is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its small research team is focused on its unique drug delivery technology. This chart shows the size of its focused R&D team working on innovative inhaled therapies.
Share of the company's employees Pulmatrix Inc. within the market segment - Pharma other
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. This chart highlights its scientific focus. It reflects the proportion of pulmonologists and aerosol drug delivery specialists working to develop effective treatments for patients with lung diseases that Pulmatrix brings together.
Number of employees in the market segment - Pharma other
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. This chart shows overall employment in the pharmaceutical industry. Growth in the pulmonology segment indicates a high demand for new treatments for conditions such as asthma and COPD, where inhaled delivery is key.
Number of employees in the market as a whole
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Pulmonology has become especially important in recent years. This graph shows overall employment, and innovations in this field not only improve quality of life but also support growth in this knowledge-intensive sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Pulmatrix Inc. (PULM)
Pulmatrix, Inc. is a pharmaceutical company, and its valuation is based on future revenue. This chart shows the market's perceived value in its R&D. High market capitalization per employee is the norm for such companies, as investors value the potential of intellectual property rather than current revenue or assets.
%20of%20the%20company%20Pulmatrix%20Inc.%20(PULM)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Pulmatrix-Inc.-PULM&v=1772513526067 "Chart of market capitalization per employee (in thousands of dollars) of the company Pulmatrix Inc. (PULM)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Pulmatrix develops inhaled medications. Its value lies in its iSPERSE drug delivery technology. Its market value per employee reflects the market's assessment of the platform's potential for treating various lung diseases. This high figure reflects high expectations for its innovative approach.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772513526088 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Pulmatrix is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases. Its inhalation delivery technology is a key asset for the company. This chart reflects how the market perceives the potential of this platform and the team's ability to create new, effective treatments.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513526105 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Pulmatrix Inc. (PULM)
Pulmatrix is a biotech company developing a platform (iSPERSE) for delivering dry powder drugs for inhalation (for example, for the lungs). This is an R&D business. This graph, being in negative territory, shows how much capital is being burned for each scientist working on this delivery technology.
%20Chart%20Pulmatrix%20Inc.%20(PULM)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Pulmatrix-Inc.-PULM&v=1772513526109 "Company Profit Per Employee (in thousands of dollars) Chart Pulmatrix Inc. (PULM)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications for the treatment of respiratory diseases using its iSPERSE™ technology. This graph highlights the potential value of their platform. It demonstrates how their innovative drug delivery technology can create products with high commercial value and, consequently, high profit potential.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772513526122 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Pulmatrix, Inc. is a biopharmaceutical company developing inhaled medications (iSPERSE technology) for the treatment of respiratory diseases. This is an R&D business. This chart reflects the investment intensity (expenses) per employee working on clinical trials and development of this unique drug delivery platform for the lungs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513526134 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Pulmatrix Inc. (PULM)
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. This graph, showing zero revenue per employee, is typical for the industry. It illustrates a period when all resources are focused on research. The success of its inhaled drugs will lead to explosive growth in this metric in the future.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Pulmatrix-Inc.-PULM&v=1772513526155 "Sales chart per company employee Pulmatrix Inc. (PULM)")
Sales per employee in the market segment - Pharma other
Pulmatrix (PULM) is a biopharmaceutical company developing inhaled medications (based on its iSPERSE™ platform) for the treatment of lung diseases. This chart shows the average revenue per employee in the pharmaceutical segment. For Pulmatrix, which is in the R&D stage, comparing it to this benchmark (zero) highlights their focus on science rather than current sales.
Sales per employee for the market as a whole
Pulmatrix (PULM) is a clinical-stage biotech developing inhaled drugs. There is no revenue. This metric is irrelevant. The company's entire value lies in the potential of its inhaled delivery technology (iSPERSE) and the success of its clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company Pulmatrix Inc. (PULM)
Pulmatrix is a biotech company developing inhaled medications (including an inhaled COVID treatment) using its iSPERSE platform. This chart shows the odds on the failure of their platform. "Bears" believe the company will fail to prove the benefits of its inhaled approach and will run out of funding for trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Pulmatrix-Inc.-PULM&v=1772513526202 "Short Shares Chart for the Company Pulmatrix Inc. (PULM)")
Shares shorted by market segment - Pharma other
Pulmatrix (PULM) is a biotech developing iSPERSE technology for inhaled drug delivery (powders) to the lungs. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that this technology is unnecessary. Investors doubt PULM will be able to prove that its powders are more effective than traditional inhalers and expect clinical trials to fail.
Shares shorted by the overall market
Pulmatrix (PULM) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing PULM won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Pulmatrix Inc. (PULM)
Pulmatrix develops inhaled medications for the treatment of pulmonary diseases. This is a complex and specialized area of biotechnology. This graph is the "pulse" of their R&D. It shows how the "temperature" of investor interest "heats up" with positive clinical trial data and "cools" during the long months of waiting for the next phases.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Pulmatrix-Inc.-PULM&v=1772513526213 "RSI 14 indicator chart for the company's stock Pulmatrix Inc. (PULM)")
RSI 14 Market Segment - Pharma other
Pulmatrix is a biopharmaceutical company developing inhaled medications (iSPERSE technology) for the treatment of lung diseases such as COPD and cystic fibrosis. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Pulmatrix (PULM) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PULM (Pulmatrix Inc.)
Pulmatrix (PULM) develops inhaled medications for respiratory diseases using its iSPERSE dry powder platform. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of this delivery technology and its chances of success in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PULM-Pulmatrix-Inc.&v=1772513526225 "A chart showing analyst consensus forecasts for the expected stock price. PULM (Pulmatrix Inc.)")
The difference between the consensus estimate and the actual stock price PULM (Pulmatrix Inc.)
Pulmatrix is a biotech company developing an inhalation platform (iSPERSE) for delivering drugs directly to the lungs. This chart shows the difference between the market valuation and the consensus forecast. It indicates whether experts believe this delivery technology will lead to effective treatments for lung diseases.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PULM-Pulmatrix-Inc.&v=1772513526234 "A chart showing the difference between the consensus forecast and the actual stock price. PULM (Pulmatrix Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Pulmatrix is a biotech company developing an inhalation platform (iSPERSE) for delivering drugs directly to the lungs. It is betting on R&D for the treatment of severe respiratory diseases. This chart reflects analysts' overall expectations across the pharmaceutical sector, demonstrating whether experts believe in the success of new inhalation technologies.
Analysts' consensus forecast for the overall market share price
Pulmatrix is a biotech company developing inhaled drugs for the treatment of lung diseases. This chart shows the overall market "risk appetite." For Pulmatrix, a high-risk clinical-stage company, overall market optimism (an upward trend in the chart) is critical for raising the capital needed to fund long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Pulmatrix Inc.
Pulmatrix is an R&D company focused on delivery. Their signature feature is iSPERSE, a dry powder inhalation technology that they claim delivers medications to the lungs far more effectively than traditional inhalers. This chart is a clear indicator of faith in their R&D platform. It reflects their (slow) progress in clinical trials and their ability to secure partnerships.
AKIMA Market Segment Index - Pharma other
Pulmatrix (PULM) is a biopharmaceutical company developing inhaled medications for lung diseases. Their iSPERSE technology delivers dry powder medications deep into the lungs. The chart shows the segment's average index, helping investors assess how this inhalation platform compares to the industry average.
The AKIM Index for the overall market
Pulmatrix is a biotech company developing inhalation therapies (iSPERSE technology) for pulmonary and central nervous system diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this drug delivery technology platform compares to overall economic trends.
